Advertisement
Heart, Lung and Circulation

Building an Academic—Industry Partnership to Tackle Australia’s Biggest Health Burden

      Cardiovascular disease (CVD) poses a highly significant health and economic burden in Australia and worldwide, with the latest global burden of disease study identifying cardiovascular disease as an “expanding threat to global health” [
      • Roth G.A.
      • Abate D.
      • Abate K.H.
      • Abay S.M.
      • Abbafati C.
      • Abbasi N.
      • et al.
      Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017.
      ]. Australian cardiovascular researchers are recognised internationally for their broad expertise spanning from fundamental molecular and cellular biology, through innovative bioengineering approaches, patient-focussed clinical trials, and impactful community interventions for improved public health. However, funding challenges have resulted in a fragmented research sector struggling to survive, let alone work together as an effective national team with strategic leadership and collaboration. The Australian Cardiovascular Alliance have successfully advocated for a federally supported Mission for Cardiovascular Helath ($220 Million). A key element of success in their goal of enhancing the CV health of Austrlaians, is partnering with industry.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Roth G.A.
        • Abate D.
        • Abate K.H.
        • Abay S.M.
        • Abbafati C.
        • Abbasi N.
        • et al.
        Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017.
        Lancet. 2018; 392: 1736-1788
        • Figtree G.A.
        • Jennings G.
        • Nicholls S.
        • Graham R.M.
        The Australian cardiovascular alliance–towards an integrated whole-of-nation strategy to address our major health burden.
        Heart Lung Circ. 2019; 28: 198-203
        • Deloitte Access Economics
        Healthcare expenditure and productivity cost savings resulting from increased intake of grain fibre in Australia.
        (Australia)2017
        • Australian Institute of Health and Welfare
        Healthcare expenditure on cardiovascular diseases 2008-09.
        (Cat.No. CVD 65. Canberra)2014
        • Lateral Economics
        The economic value of Australia’s investment in health and medical research: reinforcing the evidence for exceptional returns. A paper commissioned by research Australia.
        (Sydney, NSW)2010
        • Access Economics
        Exceptional returns: the value of investing in health research & development in Australia.
        Report for the Australian society for medical research. 2003
        • Patridge E.V.
        • Gareiss P.C.
        • Kinch M.S.
        • Hoyer D.W.
        An analysis of original research contributions toward FDA-approved drugs.
        Drug Discov Today. 2015; 20: 1182-1187
        • Gromo G.
        • Mann J.
        • Fitzgerald J.
        Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.
        Cold Spring Harb Perspect Med. 2014; 4a014092